BECOME A MEMBER
Connect with healthcare professionals around the globe to get the most up-to-date medical cannabis information.
Get Involved
TAKE OUR COURSES
The curriculum brings hands-on practical guidance on how to develop personalized treatment regimens and more.
Young adult sequelae of adolescent cannabis use: an integrative analysis.
Authors: Edmund Silins, L. John Horwood, George C. Patton, David M. Fergusson, Craig A. Olsson, et al
The Lancet Psychiatry, September 2014
—
BACKGROUND: Debate continues about the consequences of adolescent cannabis use. Existing data are limited in statistical power to examine rarer outcomes and less common, heavier patterns of cannabis use than those already investigated; furthermore, evidence has a piecemeal app…
Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010.
Authors: Marcus A. Bachhuber, Brendan Saloner, Chinazo O. Cunningham, et al
JAMA Internal Medicine, October 2014
—
IMPORTANCE: Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mort…
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation.
Authors: R J Bluett, J C Gamble-George, D J Hermanson, N D Hartley, L J Marnett, S Patel
Translational Psychiatry, 8 July 2014
—
Stress is a major risk factor for the development of mood and anxiety disorders; elucidation of novel approaches to mitigate the deleterious effects of stress could have broad clinical applications. Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling…
Prenatal cannabis exposure and infant outcomes: overview of studies.
Authors: A.C. Huizink
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 3 July 2014
—
Accumulating evidence from both human and preclinical studies indicates maternal substance use during pregnancy can affect fetal development, birth weight and infant outcomes. Thus, the prenatal period can be regarded as an important and potentially sensitive period of develop…
Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB 2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model.
Authors: Magdalena Florek-Luszczki, Aleksandra Wlaz, Maria W. Kondrat-Wrobel, et al
Journal of Neural Transmission, July 2014
—
The aim of this study was to characterize the influence of WIN 55,212-2 (WIN–a non-selective cannabinoid CB1 and CB2 receptor agonist) on the anticonvulsant effects of various classical antiepileptic drugs (clobazam, clonazepam, phenobarbital and valproate) in the mouse 6 Hz-…
Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes.
Authors: Theresa Liu, Glen T Howell, Lucy Turner, Kimberley Corace, Gary Garber, Curtis Cooper
Canadian Journal of Gastroenterology & Hepatology, July-August 2014
—
BACKGROUND: Marijuana smoking is prevalent among hepatitis C virus-infected patients. The literature assessing the influence of marijuana on liver disease progression and hepatitis C virus antiviral treatment outcomes is conflicting. METHODS: The authors evaluated hepatitis C…
The case for medical marijuana in epilepsy.
Authors: Edward Maa, Paige Figi
Epilepsia, June 2014
—
Charlotte, a little girl with SCN1A-confirmed Dravet syndrome, was recently featured in a special that aired on CNN. Through exhaustive personal research and assistance from a Colorado-based medical marijuana group (Realm of Caring), Charlotte’s mother started adjunctive thera…
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Authors: Orrin Devinsky, Maria Roberta Cilio, Helen Cross, Javier Fernandez‐Ruiz, et al
Epilepsia, June 2014
—
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant…
The case for assessing cannabidiol in epilepsy
Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014
—
Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…
Cannabis, the pregnant woman and her child: weeding out the myths.
Authors: S C Jaques, A Kingsbury, P Henshcke, C Chomchai, S Clews, J Falconer, M E Abdel-Latif, et al
Journal of Perinatology, June 2014
—
To review and summarise the literature reporting on cannabis use within western communities with specific reference to patterns of use, the pharmacology of its major psychoactive compounds, including placental and fetal transfer, and the impact of maternal cannabis use on preg…
Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders.
Authors: Barbara S. Koppel, John C.M. Brust, Terry Fife, Jeff Bronstein, Sarah Youssof, et al
Neurology, 29 April 2014
—
OBJECTIVE: To determine the efficacy of medical marijuana in several neurologic conditions. METHODS: We performed a systematic review of medical marijuana (1948-November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We gra…
Anandamide inhibits breast tumor-induced angiogenesis.
Authors: P. Picardi, E. Ciaglia, M. C. Proto, S. Pisanti
Translational Medicine, 8 April 2014
—
Breast cancer is one of the most frequently diagnosed malignancies and a leading cause of cancer death in women. Great advances in the treatment of primary tumors have led to a significant increment in the overall survival rates, however recurrence and metastatic disease, the…